UTSW Doctors Are Tackling Obesity With Medical Research

More than one out of three adults in the United States is obese. That leads to millions of deaths each year from a host of related conditions that are largely preventable, including heart disease, stroke, type 2 diabetes, and certain types of cancer. Fortunately, research by a team led by Dr. David Mangelsdorf of UT Southwestern Medical Center could help. Mangelsdorf, chair and professor of pharmacology, is looking into proteins called nuclear receptors, which flip genes on and off. Full Story

Clinical Drug Trials Aren’t Representative of America; This Group Wants to Change That

Advocates say clinical trials are not representative of the racial makeup of the United States, which could mean that treatments approved by the Food and Drug Administration will have unforeseen complications on certain demographics. A national push begun this week is aiming to change that by increasing diversity in the trials. Full Story

The FDA Just Approved a New Hepatitis-C Drug. The Price? $84,000 a Treatment.

The Food and Drug Administration last week approved a pill that is expected to make the treatment of hepatitis C easier, shorter, and more effective. Great, right? There is a downside, though: it costs $1,000 a day. The drug, Sovaldi, will allow some patients infected with the liver-destroying virus to be treated with pills only, doing away with weekly injections of a drug that is usually accompanied by debilitating side effects. That treatment can take up to a year and only cures about three out of four patients. Sovaldi is a daily pill that—in clinical trials—cured close to 90 percent of… Full Story